Voronoi In Spotlight For Brain-Permeable Lung Cancer Candidate
Korean Venture Building Platforms, Eyes IPO
South Korea’s unicorn biotech Voronoi is counting on its novel lung cancer therapy to become a game changer in the market thanks to its high target selectivity and brain permeability.
You may also be interested in...
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.